Himbert Caroline, Figueiredo Jane C, Shibata David, Ose Jennifer, Lin Tengda, Huang Lyen C, Peoples Anita R, Scaife Courtney L, Pickron Bartley, Lambert Laura, Cohan Jessica N, Bronner Mary, Felder Seth, Sanchez Julian, Dessureault Sophie, Coppola Domenico, Hoffman David M, Nasseri Yosef F, Decker Robert W, Zaghiyan Karen, Murrell Zuri A, Hendifar Andrew, Gong Jun, Firoozmand Eiman, Gangi Alexandra, Moore Beth A, Cologne Kyle G, El-Masry Maryliza S, Hinkle Nathan, Monroe Justin, Mutch Matthew, Bernadt Cory, Chatterjee Deyali, Sinanan Mika, Cohen Stacey A, Wallin Ulrike, Grady William M, Lampe Paul D, Reddi Deepti, Krane Mukta, Fichera Alessandro, Moonka Ravi, Herpel Esther, Schirmacher Peter, Kloor Matthias, von Knebel-Doeberitz Magnus, Nattenmueller Johanna, Kauczor Hans-Ulrich, Swanson Eric, Jedrzkiewicz Jolanta, Schmit Stephanie L, Gigic Biljana, Ulrich Alexis B, Toriola Adetunji T, Siegel Erin M, Li Christopher I, Ulrich Cornelia M, Hardikar Sheetal
Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84112, USA.
Cancers (Basel). 2021 Jul 29;13(15):3817. doi: 10.3390/cancers13153817.
Early-onset colorectal cancer has been on the rise in Western populations. Here, we compare patient characteristics between those with early- (<50 years) vs. late-onset (≥50 years) disease in a large multinational cohort of colorectal cancer patients ( = 2193). We calculated descriptive statistics and assessed associations of clinicodemographic factors with age of onset using mutually-adjusted logistic regression models. Patients were on average 60 years old, with BMI of 29 kg/m, 52% colon cancers, 21% early-onset, and presented with stage II or III (60%) disease. Early-onset patients presented with more advanced disease (stages III-IV: 63% vs. 51%, respectively), and received more neo and adjuvant treatment compared to late-onset patients, after controlling for stage (odds ratio (OR) (95% confidence interval (CI)) = 2.30 (1.82-3.83) and 2.00 (1.43-2.81), respectively). Early-onset rectal cancer patients across all stages more commonly received neoadjuvant treatment, even when not indicated as the standard of care, e.g., during stage I disease. The odds of early-onset disease were higher among never smokers and lower among overweight patients (1.55 (1.21-1.98) and 0.56 (0.41-0.76), respectively). Patients with early-onset colorectal cancer were more likely to be diagnosed with advanced stage disease, to have received systemic treatments regardless of stage at diagnosis, and were less likely to be ever smokers or overweight.
早发性结直肠癌在西方人群中呈上升趋势。在此,我们在一个大型跨国结直肠癌患者队列(n = 2193)中比较了早发性(<50岁)与晚发性(≥50岁)疾病患者的特征。我们计算了描述性统计数据,并使用相互调整的逻辑回归模型评估了临床人口统计学因素与发病年龄的关联。患者平均年龄为60岁,体重指数为29kg/m²,52%为结肠癌,21%为早发性,且表现为II期或III期(60%)疾病。早发性患者表现为更晚期的疾病(III - IV期分别为63%和51%),在控制分期后,与晚发性患者相比,接受新辅助和辅助治疗的比例更高(优势比(OR)(95%置信区间(CI))分别为2.30(1.82 - 3.83)和2.00(1.43 - 2.81))。所有分期的早发性直肠癌患者更常接受新辅助治疗,即使在未被列为标准治疗方案的情况下,例如在I期疾病时。从不吸烟者患早发性疾病的几率较高,超重患者的几率较低(分别为1.55(1.21 - 1.98)和0.56(0.41 - 0.76))。早发性结直肠癌患者更有可能被诊断为晚期疾病,无论诊断时处于何分期均接受了全身治疗,且更不可能曾经吸烟或超重。